As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Rein Therapeutics, Inc. The largest reported stake is Bios Capital Management, LP's, at 9.99%. 10 filings are on record since September 26, 2025 (Schedule 13G/A, May 8, 2026).
Sell to companies like Rein Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 4,500,000 · Sole dispositive: 0 · Shared dispositive: 4,500,000 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Lynwood Capital Management Inc. · Sole voting: 4,280,500 · Shared voting: 0 · Sole dispositive: 4,280,500 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Lytton Laurence W · Sole voting: 4,238,628 · Shared voting: 0 · Sole dispositive: 4,238,628 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Voss Value Master Fund, LP · Sole voting: 1,000,000 · Shared voting: 0 · Sole dispositive: 1,000,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-14
- · Holder: Lynwood Capital Management Inc. · Percent: 6.1% · SCHEDULE 13G
Rein Therapeutics, Inc. has 10 Schedule 13D or 13G filings on record since 2025-09-26. 5 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bios Capital Management, LP | 9.99% | 7,797,502 | SCHEDULE 13G/A, 2026-05-08 | 2026-05-06 |
| Funicular Funds, LP | 6.7% | 5,195,000 | SCHEDULE 13G, 2026-05-07 | 2026-05-01 |
| Voss Capital, LP | 6.6% | 5,656,957 | SCHEDULE 13G/A, 2026-07-14 | 2026-06-30 |
| ADAR1 Capital Management, LLC | 5.3% | 4,500,000 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Lynwood Capital Management Inc. | 5% | 4,280,500 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| 4.9% | 4,238,628 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
Holding shares or following this stake? See who's behind Rein Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Rein Therapeutics, Inc. and the records around it.
Rein Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Lynwood Capital Management Inc. also filed stake reports on 1 other company: Kazia Therapeutics Limited (Aug 2026)
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Pasithea Therapeutics Corp. (Apr 2026)
- Voss Value Master Fund, LP also filed stake reports on 13 other companies: Five9, Inc. (Oct 2026), Cellebrite DI Ltd. (Aug 2026), ALTA EQUIPMENT GROUP INC. (Jul 2026)
Watch Rein Therapeutics, Inc.
Get an email when Rein Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Rein Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Rein Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rein Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Voss Value Master Fund, LP | 1,000,000 | 0 | 1,000,000 | 0 | SCHEDULE 13G/A, 2026-07-14 |
| Voss Value-Oriented Special Situations Fund, LP | 500,000 | 0 | 500,000 | 0 | SCHEDULE 13G/A, 2026-07-14 |
| Voss Advisors GP, LLC | 1,500,000 | 0 | 1,500,000 | 0 | SCHEDULE 13G/A, 2026-07-14 |
| Voss Capital, LP | 4,750,000 | 906,957 | 4,750,000 | 906,957 | SCHEDULE 13G/A, 2026-07-14 |
| Cocke Travis W. | 4,750,000 | 906,957 | 4,750,000 | 906,957 | SCHEDULE 13G/A, 2026-07-14 |
| ADAR1 Capital Management, LLC | 0 | 4,500,000 | 0 | 4,500,000 | SCHEDULE 13G, 2026-08-14 |
| Daniel Schneeberger | 0 | 4,500,000 | 0 | 4,500,000 | SCHEDULE 13G, 2026-08-14 |
| Lynwood Capital Management Inc. | 4,280,500 | 0 | 4,280,500 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Ben Shapiro | 4,280,500 | 0 | 4,280,500 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Lynwood Opportunities Master Fund | 4,280,500 | 0 | 4,280,500 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Lytton Laurence W | 4,238,628 | 0 | 4,238,628 | 0 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Rein Therapeutics, Inc. by CUSIP 00887A204 and gives its principal executive office as 12407 N. Mopac Expy., Suite 250, #390, Austin, TX 78758 (SCHEDULE 13G, 2026-08-14).
What the percentages are based on
The aggregate percentage of the Shares reported owned by each person named herein is based upon 85,539,032 Shares outstanding as of May 13, 2026, which is the total number of Shares outstanding as disclosed in the Issuer's Form 10Q filed with the Securities and Exchange Commission on May 15, 2026.Voss Capital, LP, SCHEDULE 13G/A, 2026-07-14
See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 85,539,032 shares of Common Stock outstanding as of May 21, 2026, as reported by the Issuer in a Schedule 14A filed with the SEC on June 8, 2026.Lynwood Capital Management Inc., SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-26 | Voss Capital, LP | 11.3% | SCHEDULE 13G/A |
| 2026-02-13 | Voss Capital, LP | 17% | SCHEDULE 13G/A |
| 2026-05-06 | Lytton Laurence W | 5.8% | SCHEDULE 13G |
| 2026-05-07 | Funicular Funds, LP | 6.7% | SCHEDULE 13G |
| 2026-05-08 | Lynwood Capital Management Inc. | 6.1% | SCHEDULE 13G |
| 2026-05-08 | Bios Capital Management, LP | 9.99% | SCHEDULE 13G/A |
| 2026-07-14 | Voss Capital, LP | 6.6% | SCHEDULE 13G/A |
| 2026-08-13 | Lytton Laurence W | 4.9% | SCHEDULE 13G/A |
| 2026-08-14 | Lynwood Capital Management Inc. | 5% | SCHEDULE 13G/A |
| 2026-08-14 | ADAR1 Capital Management, LLC | 5.3% | SCHEDULE 13G |
Questions about who owns Rein Therapeutics, Inc.
Who owns Rein Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Rein Therapeutics, Inc.: Bios Capital Management, LP (9.99%, Schedule 13G/A, filed 2026-05-08), Funicular Funds, LP (6.7%, Schedule 13G, filed 2026-05-07), Voss Capital, LP (6.6%, Schedule 13G/A, filed 2026-07-14), ADAR1 Capital Management, LLC (5.3%, Schedule 13G, filed 2026-08-14) and Lynwood Capital Management Inc. (5%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Rein Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Rein Therapeutics, Inc. on this page are Bios Capital Management, LP (9.99%), Funicular Funds, LP (6.7%) and Voss Capital, LP (6.6%).
When did Bios Capital Management, LP buy into Rein Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bios Capital Management, LP on this page is the Schedule 13G/A, filed 2026-05-08, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Rein Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.